, George N. Konstantinou
, Georgios K. Nikolopoulos
Medical School, University of Cyprus, Nicosia, Cyprus2
Department of Internal Medicine, IRCCS San Matteo Hospital Foundation, Pavia, Italy3
ENT Department, Amsterdam University Medical Centre, Amsterdam, The Netherlands4
Postgraduate School of Allergy and Clinical Immunology, Humanitas University, Milan, Italy5
Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy6
Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece7
Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain8
Department of Pediatric Allergy, Faculty of Medicine, Gazi University, Ankara, Turkey9
Allergy Outpatient Clinic, "Laikon" General Hospital of Athens, Athens, Greece10
Department of Allergy, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain11
Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany12
Children's Hospital of Philadelphia, University of Pennsylvania Medical School, Philadelphia (PA), U.S.A.
Published: 06 September 2023
Accepted: 05 September 2023
Received: 01 June 2023
Sensitization to food and airborne allergens is common in the majority of patients with eosinophilic esophagitis (EoE). Although there is not a direct cause-effect relationship of IgE-mediated allergy with the pathogenesis of EoE, there is a growing evidence that oral desensitization to food and sublingual immunotherapy (SLIT) may induce the development of EoE as an adverse effect. As part of the 'EoE and Allergen Immunotherapy (AIT)' Task Force funded by the European Academy of Allergy and Clinical Immunology (EAACI), a systematic approach will be followed to review the evidence from the published scientific literature on the development of EoE in children and adults under any type of AIT.
This systematic review will be carried out following the PRISMA statement guidelines. Studies will be assessed for inclusion in the review according to the Population-Interventions-Comparators-Outcomes (PICO) criteria.
Expected outcomes will provide evidence on the AIT-EoE development connection.
The findings from this review will be used as a reference to provide useful guidelines for physicians treating patients with EoE and/or are practicing AIT.
PROSPERO registration ID CRD4202342591.
Eosinophilic esophagitis; allergen immunotherapy; oral desensitization.